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Abstract Patients with Fabry disease frequently develop left
ventricular (LV) hypertrophy and renal fibrosis. Due to heat
intolerance and an inability to sweat, patients tend to avoid
exposure to sunlight. We hypothesized that subsequent vitamin
D deficiency may contribute to Fabry cardiomyopathy. This
study investigated the vitamin D status and its association with
LV mass and adverse clinical symptoms in patients with Fabry
disease. 25-hydroxyvitamin D (25[OH]D) was measured in
111 patients who were genetically proven to have Fabry dis-
ease. LV mass and cardiomyopathy were assessed by magnetic
resonance imaging and echocardiography. In cross-sectional
analyses, associations with adverse clinical outcomes were
determined by linear and binary logistic regression analyses,
respectively, and were adjusted for age, sex, BMI and season.
Patients had a mean age of 40±13 years (42 % males), and a
mean 25(OH)D of 23.5±11.4 ng/ml. Those with overt vitamin
D deficiency (25[OH]D≤15 ng/ml) had an adjusted six fold
higher risk of cardiomyopathy, compared to those with suffi-
cient 25(OH)D levels >30 ng/ml (p =0.04). The mean LVmass
was distinctively different with 170±75 g in deficient, 154±
60 g in moderately deficient and 128±58 g in vitamin D
sufficient patients (p =0.01). With increasing severity of vita-
min D deficiency, the median levels of proteinuria increased, as
well as the prevalences of depression, edema, cornea verticillata
and the need for medical pain therapy. In conclusion, vitamin D
deficiency was strongly associated with cardiomyopathy and
adverse clinical symptoms in patients with Fabry disease.
Whether vitamin D supplementation improves complications
of Fabry disease, requires a randomized controlled trial.
Introduction
Patients with Fabry disease frequently develop cardiac and
renal complications, including progressive nephropathy, tran-
sient ischemic attacks, early strokes, hypertrophic cardiomyo-
pathy with arrhythmias, which can subsequently lead to death
(Breunig and Wanner 2008; Weidemann et al 2009; Wanner
et al 2010; Weidemann et al 2010). The morphological hall-
marks of Fabry cardiomyopathy consist of left ventricular
hypertrophy and replacement fibrosis. At the advanced stage
of replacement fibrosis, left ventricular function is significantly
reduced in the fibrotic segments. This structural damage and
functional loss can lead to significant heart failure and even
end-stage disease.
Vitamin D is associated with decreased cardiovascular-
related morbidity and mortality (Wolf et al 2007; Dobnig et al
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2008; Pilz et al 2008a, b; Mehrotra et al 2009; Drechsler et al
2010; Drechsler et al 2011), possibly by modifying cardiac
structure or function; however, firm evidence for either remains
lacking. Vitamin D status plays a crucial role for the myocar-
dium and vasculature. Experimental studies identified vitamin
D receptors and expression of 1α-hydroxylase in vascular
smooth muscle, endothelial cells, and possibly cardiac tissue
(Somjen et al 2005; Chen et al 2008; Chen et al 2011). These
cells and tissues may therefore be able to produce 1,25(OH)D
on a local level. Experimental data showed that vitamin D
receptor knockout and 1α-hydroxylase knockout mice develop
heart failure, despite having normal calcium levels (Bouillon
et al 2008; Pilz et al 2010).
Due to symptoms such as heat intolerance and the inability
to sweat, Fabry patients tend to avoid sunlight exposure. Often,
patients also suffer from malabsorptive gastrointestinal disease.
Both conditions may contribute to a deficiency in vitamin D. It
is equally important to note that, patients with Fabry disease
have been shown to suffer from low bone mineral density,
leading to osteopenia and osteoporosis, further linking vitamin
D deficiency to the disease (Germain et al 2005; Mersebach
et al 2007). Given the link between vitamin D deficiency and
abnormalities in cardiac structure and function, we hypothe-
sized that vitamin D deficiency may contribute to the cardio-
myopathy observed in Fabry patients. This study investigated
the vitamin D status and its association with left ventricular
mass and hypertrophy, as well as adverse clinical symptoms in
a large cohort of patients with Fabry disease.
Methods
Study population
Between 2001 and 2009, 111 patients with genetically con-
firmed Fabry disease were seen at the Fabry Centre for
Interdisciplinary Therapy inWürzburg and were included into
this study upon their first visit. Inclusion criteria for the
present study were (1) genetically proven Fabry disease and
(2) availability of blood samples for measurement of 25(OH)
vitamin D. For the analysis, we divided the cohort according
to their baseline 25(OH) vitamin D levels into groups based on
overt deficient <15 ng/ml (<37 nmol/l), moderately deficient
15–30 ng/ml and sufficient >30 ng/ml (75 nmol/l) serum
levels in line with established categorizations used in the
literature (Mehrotra et al 2008; Wang et al 2008). Clinical
symptoms and renal parameters were assessed. Parameters of
cardiac function were measured by echocardiography and
magnetic resonance imaging.
All procedures followed were in accordance with the eth-
ical standards of the responsible committee on human exper-
imentation (institutional and national) and with the Helsinki
Declaration of 1975, as revised in 2000. The ethics committee
approved the research protocol. Written informed consent was
obtained from all patients for being included in the study.
Data collection
Information on age, gender, smoking status and history of hy-
pertension was obtained through patient interviews. Systolic and
diastolic blood pressure was measured in sitting position after
5 min rest. Body mass index (BMI) was calculated as weight
(kg) divided by height (m) squared. Comorbidities, including the
presence of coronary artery disease, congestive heart failure, and
cardiac dysrhythmia were obtained from patient reports and the
patients’ clinical records. In addition, we asked the patients about
specific symptoms of Fabry disease, including the presence of
anhidrosis, acroparesthesia, heat- and physical stress intolerance,
pain, nausea and diarrhea. A physical examination was
performed by a medical doctor who was specifically trained in
the care of patients with Fabry disease. We recorded information
about kidney transplantation and dialysis. Urinary protein excre-
tion was determined in 24 h urine samples.
Levels of 25(OH)D were measured in serum samples
taken at baseline; i.e. prior to any enzyme replacement
therapy with galactosidase A. Samples were stored without
repeated freeze thaw cycles at −80 °C until measurement.
Serum concentrations of 25(OH)D were measured by
means of a chemiluminescence assay (IDS, iSYS 25(OH)D;
Immunodiagnostic systems Ltd, Boldon, UK) on an IDS-iSYS
multi-discipline automated analyser.Within-day coefficients of
variation were 5.5–12.1 % and inter–day coefficients of vari-
ation were 8.9–16.9 %, respectively. Routine haematological
and biochemical parameters were all determined in a
central laboratory at the Würzburg University hospital.
The Glomerular filtration rate was measured by the clearance
of Technetium-99m labeled DTPA (99Tc diethylene-
triaminepentaacetic acid).
MR-tomography and standard echocardiographic
measurements
A routine cine-MRIwas performed in 81 patients as part of the
standard assessment (LV heart mass and MR-ejection frac-
tion) on a Siemens Sonata-Avanto (Erlangen, Germany) or a
Philips Gyroscan ACS-NT (Best, Netherlands) 1,5 T Full-
Body-Scanner (Beer et al 2006). Reasons for the missing
examinations were claustrophobia, metal implantations or
missing consent.
Patients were lying on their left side for the echocardiographic
examination. Echocardiography was performed using a GE
Vingmed Vivid 7 (Horten, Norway; 3.5 Mhz). LVend-diastolic
(LVEDD) and end-systolic dimensions (LVESD), as well as
end-diastolic thickness of the posterior wall (LVPWD) and the
septum (IVSD), were measured using standard M-mode echo-
cardiographic methods from parasternal LV long axis images.
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TheDevereux formula, indexed to body surface area and gender,
was used to calculate the LV mass. Normal values for end-
diastolic wall thickness (both posterior and septal wall thickness)
are <11 mm for women and <12 mm for men, respectively.
Based on these cut-off values, we determined the presence of
hypertrophy of the posterior wall, hypertrophy of the septum,
and hypertrophy in general within patients. Hypertrophy in
general was documented if either posterior or septal hypertrophy
or both were present. Normal values for left ventricular mass
include 67–162 g in women and 88–224 g in men. Fractional
shortening was measured (FS=(LVDD-LVSD)/LVDD).
Ejection fraction (EF) was calculated using the modified
Simpson method. Blood pool pulsed Doppler of the mitral valve
inflow was used to extract the ratio of early-to-late diastolic flow
velocity (E/A) and the deceleration time as a parameter to
evaluate diastolic dysfunction.
Data analysis
Continuous variables were expressed as mean with standard
deviation or median with interquartile range (IQR) as appro-
priate, and categorical variables were expressed as percentages.
Differences between groups were tested using ANOVA for
continuous parameters and the chi-square test for categorical
parameters, respectively.
The study population was divided into three groups according
to their 25(OH)D status at baseline. Patients were grouped into
overt vitamin D deficient (≤15.0 ng/ml), moderately vitamin D
deficient (>15 ≤30 ng/ml), and vitamin D sufficient (>30 ng/ml)
(Mehrotra et al 2008; Wang et al 2008). We assessed the associ-
ation of baseline 25(OH)D with LV mass, cardiomyopathy and
adverse clinical symptoms. The patientswith sufficient 25(OH)D
levels were used as the reference group. By logistic regression
analyses, odds ratios (ORs) and corresponding 95 % confidence
intervals were calculated. The analyses were adjusted for the
following confounders: age, sex, BMI and season (summer/
winter). A p-value of <0.05 was considered as indicating statis-
tical significance. All p-values are reported as two-sided.
Analyses were performed using SPSS version 16.0.
Results
Patients had a mean age of 40±13 years, and 47 (42 %) of the
patients were male. The mean 25(OH)D concentration was
23.5±11.4 ng/ml. Of all patients, 26 % had overt vitamin D
deficiency (<15 ng/mL) and 47 % had moderate vitamin D
deficiency (>15 ≤30 ng/ml). Patients had on average a normal
BMI (mean 23.5±4.2 kg/m2) and normal blood pressure (mean
124/81 mmHg). Regarding comorbidities, about one third
(32 %) of the patients had elevated blood pressure (> 130/
80 mmHg), 34 % suffered from heart failure and 9 % had
angina pectoris. Themean glomerular filtration rate was normal
(93±35 ml/min). On average, patients did not have overt pro-
teinuria (89 mg/day). The baseline characteristics of the Fabry
patients are presented in Table 1.
Cardiac and renal function by vitamin D status
Of all patients, nine patients (8 %) had a vitamin D level below
10 ng/ml, and 15 patients (14 %) had a vitamin D level below
12 ng/ml.When using 15 ng/ml as a cutoff for severe vitamin D
deficiency, a total of 29 patients (26 %) were affected and were
used for subsequent analyses. Patients with moderate or overt
vitamin D deficiency more often had cardiac hypertrophy than
patients with sufficient vitamin D status. General cardiac hy-
pertrophywas present in 72% of the patients with overt vitamin
D deficiency, and in 78 % of the patients with moderate
deficiency, while it was present in 35 % of the vitamin D
sufficient patients only (Table 2). The mean LV mass was
substantially different with 170±75 g in overt deficient, 154±
60 g in moderately deficient and 128±58 g in vitamin D
sufficient patients (p =0.01). Regarding renal status, the per-
centage of patients with proteinuria (> 150 mg/24 h) was 35 %
in the group of vitamin D sufficient patients, and slightly higher
with 48 % and 46 % in the groups with moderate and overt
vitamin D deficiency, respectively.
We performed logistic regression analyses to evaluate the
risks of adverse cardiac and renal symptoms controlling for
the following confounders: age, sex, BMI and season
(summer/winter). By adjusted analyses, patients with overt
vitamin D deficiency (25[OH]D≤15 ng/ml) had a 6 fold




Sex % female 58
25(OH) vitamin D ng/ml 23.5±11.4
BMI kg/m2 23.5±4.2
Systolic blood pressure mmHg 124±17
Diastolic blood pressure mmHg 81±11
Arterial hypertension % 32
Cardiovascular disease
Angina % 9.1
NYHA I-II % 34
Arrhythmia % 14.7
Renal status
Serum creatinine mg/dl 1.0±0.6
GFR ml/min 93±35
Proteinuria mg /day 89 (23–597)
Values are presented as means and standard deviation or median and
interquartile range
BMI Body mass index; GFR Glomerular filtration rate
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higher risk of cardiac hypertrophy, compared to those with
sufficient 25(OH)D levels >30 ng/ml (HR 6.4, 95 % CI 1.1–
38.8, p =0.04). Similarly, the adjusted risk of septal hypertro-
phy was six fold increased (HR 6.1, 95 % CI 1.1–36.5, p =
0.04). The odds ratio for heart failure was 2.4 (0.6–9.3) in
overt vitamin D deficiency and 2.9 (0.9–9.2) in moderate
vitamin D deficiency.We did not find any association between
vitamin D deficiency, hypertension or arrhythmia. The results
of all further logistic regression analyses are presented in
Fig. 1.
Clinical symptoms of vitamin D status
Furthermore, adverse clinical symptoms more often occurred
in patients with vitamin D deficiency, as compared to those
with vitamin D sufficiency. Patients with vitamin D deficiency
experienced chronic pain, depression, and were often in need
of medical pain therapy. Similarly, the prevalences of edema,
diarrhea, heat intolerance and cornea verticillata were higher
for patients with vitamin D deficiency (Table 2).
Logistic regression analyses were performed to evaluate
the risks of adverse clinical symptoms associated with vitamin
D status, adjusting for confounders including age, sex, BMI
and season. The results of the logistic regression analyses for
the occurrence of clinical symptoms are presented in Fig. 1.
Discussion
The present study investigated the vitamin D status in patients
with Fabry disease. We evaluated the associations of vitamin
D status with cardiac and renal complications, as well as with
clinical symptoms. We found that vitamin D deficiency was
prevalent (73 %) among Fabry patients. Vitamin D deficiency
was associated with hypertrophic cardiomyopathy and an
increased left ventricular mass. With increasing severity of
vitamin D deficiency, the median levels of proteinuria in-
creased, as well as the prevalences of depression, edema,
cornea verticillata and the need for medical pain therapy.
In general, vitamin D from either ultraviolet-B induced syn-
thesis in the skin or from nutritional intake is hydroxylated to 25-
hydroxyvitamin D (25[OH]D) in the liver, circulating up to 1000
fold higher concentrations than the most potent vitamin Dmetab-
olite 1,25-dihydroxyvitamin D (1,25[OH]2D) (calcitriol) (Dusso
et al 2005). The renal production of 1,25(OH)2D is dependent on
substrate availabilitywhen circulating 25(OH)D is low. In patients
with chronic diseases, limited sunlight exposure and reduced
capacity of the skin to synthesize vitamin D, as well as a loss of
vitamin D binding protein in the urine, are mainly responsible
for the high prevalence of depressed 25(OH)D levels (Jacob
et al 1984; Wolf et al 2007; Wang et al 2008; Mehrotra et al
2009). Fabry patients typically suffer from so-called Fabry
crises due to heat intolerance, especially during the summer.
Patients systematically avoid outdoor activities and, thus, are
potentially at risk of developing insufficient vitamin D levels.
The treatment of Fabry disease today focuses on relieving
symptoms, supporting organs and arresting disease progression.
Enzyme replacement therapy with alpha or beta galactosidase A
is administered to patients with Fabry disease, but some patients
do not respond well to the treatment. So-called adjunctive ther-
apies and treatment strategies are currently being discussed to
support patients with Fabry disease and improve morbidity,
mortality and quality of life. In this context, a sufficient blockade
of the renin-angiotensin-aldosteron system is widely advocated,
but adequate vitamin D storages or supplementation may also be
necessary. However, we do not yet advise vitamin D therapy on
the basis of our data, although nutritional vitamin D supplemen-
tation is widely recommended. The present findings are obser-
vational and cannot prove causality.
Interestingly, anti-hypertrophic and anti-proliferative ac-
tions of vitamin D metabolites have recently been reported
(Pilz et al 2010). In hypertrophic hearts, an increased expres-
sion of the VDR has been found in cardiac myocytes and
fibroblasts (Chen et al 2008). Experimental studies have found
that cardiac myocytes and fibroblasts express the enzymes 1α-
Table 2 Cardiac, renal status and clinical symptoms by vitamin D
category
25(OH) vitamin D ng/ml
≤15 >15≤30 >30
N=29 N=52 N=30
Age years 37±10 43±14 38±12
Male sex % 52 44 30
BMI kg/m2 24.9±4.9 23.0±3.8 22.9±3.7
Systolic RR mmHg 124±17 129±18 117±14
Diastolic RR mmHg 85±11 80±11 81±11
LV mass g 170±75 154±60 128±58
Hypertrophy septum % 64 69 30
Hypertrophy posterior % 54 69 30
Hypertrophy general % 72 78 35
Ejection fraction % 62 65 60
Proteinuria % 46 48 35
Proteinuria mg/day 118 (30–715) 102 (34–602) 66 (0–416)
Clinical symptoms
Chronic pain % 52 48 31
Pain therapy % 37 12 11
Depression % 17 6 8
Edema % 35 22 11
Heat intolerance % 69 57 46
Cornea verticillata % 50 53 27
Diarrhea % 39 30 29
Values are presented as means and standard deviation or median and
interquartile range or percentages, as appropriate
LV Left ventricular
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hydroxylase and 24-hydroxylase (Akeno et al 1997; Chen et al
2008). The conversion of 25(OH)D to 1,25(OH)2D by 1α-
hydroxylase is mainly dependent on substrate availability.
Therefore, the concentrations of circulating 25(OH)D may be
a significant determinant of vitamin D effects in the myocardi-
um. In addition, vitamin D receptor activation was reported to
modulate cardiac calcium flux, thus inducing an accelerated
relaxation of cardiomyocytes. This, in turn, may improve the
diastolic function of the heart (Pilz et al 2010). Finally, vitamin
D deficiency has been found associated with congestive heart
failure (Pilz et al 2008a, b) including infants with vitamin D–
deficient rickets (Brown et al 2009). In animal studies, calcitriol
or related analogs such as paricalcitol attenuated left ventricular
hypertrophy (Chen et al 2011), augmented diastolic relaxation
and reduced end-diastolic pressures. Furthermore, a reduction
of cardiac mRNA expression, blood levels of natriuretic pep-
tides, and episodes of congestive heart failure have been ob-
served (Bodyak et al 2007; Tishkoff et al 2008; Przybylski et al
2010; Bae et al 2011). Despite the encouraging experimental
and clinical data from previous studies, we cannot prove cau-
sality from our observational data. We, therefore, cannot rule
out reverse causation, i.e. that vitamin D deficiency is a conse-
quence of left ventricular hypertrophy and heart failure and thus
reflects a cardiac disease’s severity. The most advanced Fabry
patients (suffering from heart failure, fatique, hypohidrosis)
may tend to avoid sun exposuremost and those with proteinuria
are on top loosing the vitamin. Therefore, vitamin D may be
merely a marker with low levels reflecting disease severity.
With increasing severity of vitamin D deficiency, the median
levels of proteinuria in our patients increased. Knockout of the
vitamin D receptor in diabetic mice was associated with severe
albuminuria and glomerulosclerosis from increased thickening
of the glomerular basement membrane and podocyte effacement
(Zhang et al 2008a, b). Moreover, combined treatment with
paricalcitol and an angiotensin receptor blocker in models of
diabetic nephropathy prevented the development of albuminuria,
maintaining the structure of the glomerular filtration barrier, and
reducing glomerulosclerosis, in association with a reduced renal
expression of renin (Zhang et al 2008a, b). A recent randomized
controlled trial demonstrated a reduction of residual albuminuria
in patients with diabetic nephropathy (de Zeeuw et al 2010),
whereupon 2 μg/day paricalcitol were added to a sufficient
inhibition of the renin-angiotensin-aldosteron system.
Conclusion
In conclusion, our study shows that vitamin D deficiency is
associated with the development of complications in patients
with Fabry disease, to include progressive Fabry nephropathy,
hypertrophic cardiomyopathy and adverse clinical symptoms. It
remains to be proven whether vitamin D deficiency is a risk
factor for these complications or merely a marker of disease
severity. This is important for the development of novel strate-
gies as additional treatment interventions for patients with Fabry























Fig. 1 Odds ratios for the relation between vitamin D status and clinical
outcomes, adjusted for age, sex, BMI and season. The odds ratios are
presented with 95 % confidence intervals for the patients with overt
25(OH)D deficiency (black) and moderate 25(OH)D deficiency (grey),
as compared to the patients with 25(OH)D sufficiency (reference group)
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patients with Fabry disease and improve morbidity, mortality
and quality of life. In this context, novel studies are needed to
validate the potential use of vitamin D status as a marker for
disease progression. Importantly, further research is required to
establish the role of vitamin D status as potential intervention
target. A randomized multicenter controlled trial is required to
clarify if vitamin D supplementation improves the complications
of Fabry disease.
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